The study, which will be led by Dr Christine Chiaverini, a dermatologist who works at the Centre Hospitalier Universitaire de Nice in France, will involve clinical testing with up to twenty people, aged six years or older, who have severe EBS which causes at least four new blisters every day.

It is estimated that the study will involve twenty weeks of testing for each person: after an initial screening they will take the tablets for eight weeks, stop for four weeks, then take the tablets again for a further eight weeks. Outcomes such as blistering, pain, itch and quality of life will be measured during periods with and without treatment and compared. Positive results will support the next step of a placebo controlled clinical trial.

In total the clinical trial is set to take two years to complete.